Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation

Description

Study to Evaluate the safety and efficacy of a Latanoprost/Minoxidil formulation vs. placebo for the treatment of hypotrichosis of the eyebrows.

Conditions

Hypotrichosis

Study Overview

Study Details

Study overview

Study to Evaluate the safety and efficacy of a Latanoprost/Minoxidil formulation vs. placebo for the treatment of hypotrichosis of the eyebrows.

Proof of Concept of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation for Eyebrows

Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation

Condition
Hypotrichosis
Intervention / Treatment

-

Contacts and Locations

Indian Wells

WellMax, Indian Wells, California, United States, 92210

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients with diagnosed hypotrichosis of the eyebrows.
  • * Subjects with active hair loss within the last 12 months.
  • * Patients willing to refrain from initiation of any new vitamins or nutritional supplements for the duration of the study.
  • * Patients willing to refrain from use of any hair growth therapies (oral or topical) other than the investigational product.
  • * History of hair transplants, scalp reduction, current hair weave or tattooing in the target area, artificial hair coloring two months prior to initiation of study which makes it difficult to perform hair count assessment.
  • * Subjects with hair loss for greater than 5 years, as medical therapy is unlikely to have much effect at restoring hair follicles inactive for that long of a time period.
  • * Subjects with a history of chemotherapy, receiving cytotoxic agents, radiation, or laser/surgical therapy of the scalp within the past 12 months.
  • * Any known or underlying medical problem that could influence hair growth such as HIV infection, connective tissue disease, a thyroid condition, inflammatory bowel disease or other medical conditions, at the discretion of the investigator.
  • * Subjects with clinical diagnosis of hair loss other than hypotrichosis of the eyebrows.
  • * Subjects with severe cardiovascular disease, uncontrolled or untreated hypertension, arrythmia or clinically relevant hypotension.
  • * Subjects with known or suspected hypersensitivity or allergic reaction to any of the active or inactive components of the test articles.
  • * Pregnant or lactating females or planning to become pregnant for the duration of the study.
  • * Subjects using medications that potentially cause drug-induced hair loss (e.g., depotestosterone, haloperidol, methotrexate, methylprednisolone, prednisone, testosterone, divalproex sodium) within the last 3 months.
  • * Current enrollment in any other investigational medication (drug) study within the 4 weeks prior to study initiation.
  • * Current or recent (2 months) history of severe diet or eating disorder.

Ages Eligible for Study

22 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Aneira Pharma, Inc.,

Dan Cosgrove, M.D., PRINCIPAL_INVESTIGATOR, WellMax

Study Record Dates

2023-06-30